🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join CLL Society on April 17th to learn about taking a comprehensive approach to your health and wellness while living with CLL. Dr. Deborah Stephens will discuss topics such as diet & exercise, mind-body practices, supplements, and more. Register at: bit.ly/4l3Ukmv

The immune challenges for our patients are becoming well documented. clladvocates.net/whitepaper-cll… This will be of interest to learn the latest developments in managing viral infections.

"LLC: O passado, o presente e o futuro", com o Prof. Michael Hallek. #abhh #blc2025 #hematologia #hemoterapia #terapiacelular #transplantedemedulaóssea #linfoma #cartcell #imunoterapia #quimioterapia

Exciting news to share that this year’s CLL Horizons will be hosted in Krakow, Poland, from 11–13 September. Registration details to follow soon.....

New #EHAUnplugged episode available now - Hematology Portrait with Prof António Almeida, EHA President. This series of podcasts dives into the careers of well-established hematology experts, sharing their learnings along the way.  Tune in to hear Prof António talk about his

Just out Blood Advances Zanubrutinib in patients who didn't tolerate ibrutinib or acalabrutinib. Updated results. pubmed.ncbi.nlm.nih.gov/40334067/ #CLL Jeff Sharman Fred Hutch Cancer Center

🧪 National Cancer Research Month is a time to spotlight the importance of advancing research that improves outcomes for people affected by cancer. According to findings from the most recent Global Patient Survey (GPS) on Lymphomas and CLL: 🔹 77% of respondents were aware that

Delighted to meet Liam Gallagher and see the amazing work of vincentdevineart on display at this important event #CancerMissionFair in Poland. Also proud to represent CLL Advocates Network and our CLL community. CLL Ireland #ECHoS

🔍 Best Practice Session now at #CMLHZ25 Chaired by Jana Pelouchová & Milica Kuzmanoska 💬 In this session, we shine a light on the incredible work of our members around the world 🌍 First up: 🇨🇦 Cheryl-Anne Simoneau from the CML Society of Canada, sharing how Value-Based

Wishing our friends in CML AdvocatesNetwork all the best for a successful CML Horizons conference in Bucharest. Powerful advocacy and learning to make sure all patients and their families have access to the best care and treatments around the world. #CML

Regional meeting reports in progress at #cmlhz25

Today is 𝐖𝐨𝐫𝐥𝐝 𝐁𝐥𝐨𝐨𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐚𝐲 2025, a day dedicated to raising awareness and support for those affected by blood cancers, including Chronic Lymphocytic Leukemia (CLL). #BloodCancer #Leukemia #Leukeamia

Lymphoma Coalition is pleased to share the upcoming symposium & webinar hosted by NCCN in collaboration with Clinical Care Options: Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course This interactive, case-based discussion

CLL Advocates Network at #EHA25 poster and abstract focus on advancing shared decision-making in CLL, ensuring that care reflects the individual goals, preferences, and values of those living with the disease. library.ehaweb.org/eha/2025/eha20…

WH25244 as a new promising proapoptotic targeted agent to overcome VEN/BTKi resistant #CLL. Excellent translational research work presented at LBA session at #EHA2025 #hematology

#EHA2025, it's a wrap! Thank you to all our delegates, faculty and partners for joining us in Milan for 3.5 days of learning and connection. We look forward to seeing you again next year in Stockholm from 11-14 June for #EHA2026. Save the date!

Updates from EHA2025 in #CLL The Flair trial saw two targeted cancer drugs perform better than standard chemotherapy, halting disease progression in 94% of patients.

Presented at #EHA2025: Among patients with CLL undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial nej.md/3SMNdC4

Original Article: Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia (FLAIR phase 3 trial) nej.md/3SMNdC4   #EHA2025 | European Hematology Association